Drugs / PF-07284892
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06704724 | Dec 2024 → May 2026 | colorectal neoplasm, non-small cell lung carcinoma, pancreatic ductal adenocarcinoma | Pfizer | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT04800822 | Mar 2021 → Jun 2024 | neoplasm | Pfizer | Terminated | No outcome recorded Stop: Business |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PF-07284892 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06704724 ↗ |
| Known as | ARRY-558 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5543051 ↗ |
| Modality | Small molecule | — CHEMBL5543051 ↗ |